A part of Watch Media

MedWatchWednesday1 February 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
09/12/2022at 12:50

Board chair at Coloplast and Lundbeck warns against large pay rises

Companies have a responsibility to help combat inflation by keeping pay rises in check during contract negotiations, says Lars Rasmussen.
Lars Rasmussen, chairman of the board at Lundbeck and Coloplast. | Photo: Niels Hougaard
by ulrich quistgaard, translated by catherine brett

Companies should think twice before granting pay rises in line with inflation during upcoming contract negotiations, says Lars Rasmussen, chairman of the board at both Coloplast and Lundbeck, tells Danish business daily Børsen.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters

Get full access for you and your coworkers

Start a free company trial today

Related articles:

  • Photo: Novo Nordisk / PR/Henning Larsen Architects

    Retention, retention, retention – Danish life science firms shower employees in extra benefits

    For subscribers

  • Photo: Mads Andreas Frost/ERH

    Life science CEOs' paychecks decrease as markets decline

    For subscribers

  • Novo Nordisk's employees will have their remuneration regulated at the end of the year instead of having to wait until Q1 or Q2, 2023 | Photo: Novo Nordisk / PR

    Employment researcher: Novo Nordisk salary advances are part of retention strategy

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Lars Fruergaard Jørgensen, CEO at Novo Nordisk | Foto: Stine Bidstrup
Pharma & biotech

Potential blockbuster submitted by Novo Nordisk for European approval

The EMA can begin reviewing hemophilia treatment concizumab, which used to carry the orphan drug badge until recently, when the company decided not to take advantage of the status.
  • Novo Nordisk renounces orphan drug title for potential blockbuster
  • Rare Disease business comes in slightly below expectations for Novo Nordisk

For subscribers

Viatris's headquaters in Pittsburgh, Pennsylvania, US | Foto: Viatris/PR.
Pharma & biotech

Novo Nordisk sues Viatris over copycat Wegovy

For subscribers

Foto: Arnd Wiegmann/Reuters/Ritzau Scanpix
Pharma & biotech

Novartis beats Kesimpta sales expectations in Q4

For subscribers

Foto: Andrew Kelly/Reuters/Ritzau Scanpix
Pharma & biotech

Analyst: Strong Novo Nordisk outlook should satisfy investors

For subscribers

Foto: Jens Dresling/Ritzau Scanpix
Pharma & biotech

Studies of Wegovy in higher-than-approved doses begin

For subscribers

Foto: Novo Nordisk
Pharma & biotech

Rare Disease business comes in slightly below expectations for Novo Nordisk

For subscribers

Further reading

Christian Hedegaard, investment Director at Nordic Capital | Foto: NordicCapital
Pharma & biotech

ESG compliance makes companies more attractive

ESG questions played a role when Nordic Capital invested in Leo Pharma in 2021, and the private equity firm says ESG is only becoming more and more important.

For subscribers

Foto: Tidsvilde Stine/Ritzau Scanpix
Pharma & biotech

Novo Nordisk declared world's best place to work in 2022

The Best Places to Work organization has released its 2022 list of the best workplaces across the world, and Danish Novo Nordisk shines at the top.

For subscribers

Foto: Leo Pharma / Pr
Pharma & biotech

Spokesperson: Laid-off Leo employees have leg-up in job hunt at Novo and Lundbeck

Dismissed Leo Pharma workers get to skip the line when looking for jobs at Novo Nordisk and Lundbeck via a new job tunnel – and Bavarian Nordic would like to snatch a few people up, too.

For subscribers

Latest news

  • Potential blockbuster submitted by Novo Nordisk for European approval – 13:51
  • Novo Nordisk sues Viatris over copycat Wegovy – 12:46
  • Novartis beats Kesimpta sales expectations in Q4 – 11:49
  • Analyst: Strong Novo Nordisk outlook should satisfy investors – 11:09
  • Studies of Wegovy in higher-than-approved doses begin – 10:01
  • Rare Disease business comes in slightly below expectations for Novo Nordisk – 09:48
  • Novo Nordisk meets upgraded guidance, setting new revenue record – 09:20
  • Novo Nordisk doubles obesity sales in 2022 – 08:54
  • Maersk and German start-up wants to enhance emission visibility for global e-trade – 08:27
  • Novo Nordisk predicts wide range for 2023 sales growth – 07:38
See all

Jobs

  • Head of Regulatory Affairs Danmark

  • Application Manager

  • Lead Data Architect

  • Sr. Director, Drug Safety Physician

  • Application Manager

  • Regulatory Affairs Professional

  • Commercial Director

  • Clinical Operational Associate

  • Experienced Patent Counsel

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Senior Regulatory Affairs Professional

See all jobs

Jobs

  • Head of Regulatory Affairs Danmark

  • Application Manager

  • Lead Data Architect

  • Sr. Director, Drug Safety Physician

  • Application Manager

  • Regulatory Affairs Professional

  • Commercial Director

  • Clinical Operational Associate

  • Experienced Patent Counsel

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Senior Regulatory Affairs Professional

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge